Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection
Authors:
- A C J Van AkkooiAAA C J Van Akkooi
- P RutkowskiPRP Rutkowski
- M CookMCM Cook
- O E NiewegONO E Nieweg
- C R RossiCRC R Rossi
- A TestoriATA Testori
- S SuciuSSS Suciu
- C VerhoefCVC Verhoef
- A M M EggermontAEA M M Eggermont
- European Organization for Research and Treatment of Cancer Melanoma GroupEGEuropean Organization for Research and Treatment of Cancer Melanoma Group
Open Access
- 7 September 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 99 (10) , 1396-1405
Abstract
The therapeutic value of immediate completion lymph node dissection (CLND) for sentinel node (SN)-positive melanoma is unknown. The aim of this study was to evaluate the impact of immediate CLND on the outcome of patients with SN-positive melanoma. Patients with SN metastases treated between 1993 and 2008 at ten cancer centres from the European Organization for Research and Treatment of Cancer Melanoma Group were included in this retrospective study. Maximum tumour size, intranodal location and penetrative depth of SN metastases were measured. Outcome in those who had CLND was compared with that in patients who did not undergo completion lymphadenectomy. Of 1174 patients with SN-positive melanoma, 1113 (94·8 per cent) underwent CLND and 61 (5·2 per cent) did not. Median follow-up for the two groups was 34 and 48 months respectively. In univariable survival analysis, CLND did not significantly influence disease-specific survival (hazard ratio (HR) 0·89, 95 per cent confidence interval 0·58 to 1·37; P = 0·600). However, patients who did not undergo CLND had more favourable prognostic factors. Matched-pair analysis, with matching for age, Breslow thickness, tumour ulceration and SN tumour burden, showed that CLND had no influence on survival (HR 0·86, 0·46 to 1·61; P = 0·640). After adjusting for prognostic factors in multivariable survival analyses, no difference in survival was found. In these two cohorts of patients with SN-positive melanoma and prognostic heterogeneity, outcome was not influenced by CLND.Keywords
This publication has 31 references indexed in Scilit:
- Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography CriteriaJournal of Clinical Oncology, 2011
- EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam CriteriaEuropean Journal of Cancer, 2010
- Outcome of Patients with a Positive Sentinel Lymph Node who do not Undergo Completion LymphadenectomyAnnals of Surgical Oncology, 2009
- Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma PatientsAnnals of Surgery, 2008
- Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent RelapseAnnals of Surgical Oncology, 2006
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006
- Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?Annals of Oncology, 2006
- Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional StudyAnnals of Surgical Oncology, 2006
- The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node InvolvementJournal of Clinical Oncology, 2004
- Sentinel Lymphonodectomy and S-Classification: A Successful Strategy for Better Prediction and Improvement of Outcome of MelanomaAnnals of Surgical Oncology, 2004